A Pilot Study on the Efficacy and Safety of Sedation With Remimazolam in Japanese Patients Undergoing Endoscopic Retrograde Cholangiopancreatography
Journal of Hepato-Biliary-Pancreatic Sciences · 2025
DOI: 10.1002/jhbp.70018 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Hepato-Biliary-Pancreatic Sciences, 2025. Verfasst von Shuhei Shintani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Shiga University of Medical Science, Otsu, Japan. Hauptthemen laut MEDLINE: Cholangiopancreatography, Endoscopic Retrograde, Benzodiazepines, Pentazocine, Hypnotics and Sedatives. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Objectives
Remimazolam is a novel, ultra‐short‐acting benzodiazepine. Remimazolam is characterized by rapid induction and recovery and low cardiopulmonary effects. The present study aimed to examine the safety and efficacy of a sedation method combining remimazolam and pentazocine during endoscopic retrograde cholangiopancreatography (ERCP) in a Japanese cohort.
Methods
The present investigation was a single‐center, single‐arm, Phase 2 study. The primary endpoint was successful endoscopic sedation. The initial dose was induced with remimazolam (0.1 mg/kg) and pentazocine (3.75 mg). Remimazolam (0.05 mg/kg) and the same dose of pentazocine as the initial dose were added as needed in response to body movements or signs of discomfort during the procedure.
Results
A total of 59 patients [median age (range): 75 years (48–87 years), 47 male (79.7%)] were enrolled. Successful endoscopic sedation was achieved in all patients. One patient (1.7%) experienced transient circulatory depression, with no instances of respiratory depression or need for flumazenil reversal. Post‐procedure alertness was achieved within 5 and 10 min in 52 (88.1%) and 58 patients (98.3%), respectively.
Conclusion
Sedation with remimazolam and pentazocine in ERCP demonstrated high efficacy and a favorable safety profile in the Japanese population. Trial Registration This trial was registered in the Japan Registry of Clinical Trials (jRCTs051230088)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Shiga University of Medical Science, Otsu, Japan.
- Department of Anesthesiology, Shiga University of Medical Science, Otsu, Japan.
- Center for Clinical Research and Advanced Medicine, Shiga University of Medical Science, Otsu, Japan.
ORCID-Profile: Shuhei Shintani, Takayoshi Mizuno, Jun Matsubayashi
Zitieren
APA
Shintani, S., Mizuno, T., Matsubayashi, J., Okamoto, T., Hiroe, K., Nishida, A., Kitagawa, H., Inatomi, O., & Iwashita, T. (2025). A Pilot Study on the Efficacy and Safety of Sedation With Remimazolam in Japanese Patients Undergoing Endoscopic Retrograde Cholangiopancreatography. Journal of Hepato-Biliary-Pancreatic Sciences. https://doi.org/10.1002/jhbp.70018
Vancouver
Shintani S, Mizuno T, Matsubayashi J, Okamoto T, Hiroe K, Nishida A, et al. A Pilot Study on the Efficacy and Safety of Sedation With Remimazolam in Japanese Patients Undergoing Endoscopic Retrograde Cholangiopancreatography. Journal of Hepato-Biliary-Pancreatic Sciences. 2025. doi:10.1002/jhbp.70018
BibTeX
@article{Shintani2025,
author = {Shintani, Shuhei and Mizuno, Takayoshi and Matsubayashi, Jun and Okamoto, Takuya and Hiroe, Kosuke and Nishida, Atsushi and Kitagawa, Hirotoshi and Inatomi, Osamu and Iwashita, Takuji},
title = {A Pilot Study on the Efficacy and Safety of Sedation With Remimazolam in Japanese Patients Undergoing Endoscopic Retrograde Cholangiopancreatography},
journal = {Journal of Hepato-Biliary-Pancreatic Sciences},
year = {2025},
doi = {10.1002/jhbp.70018}
}
EUVIMED